8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 17, 2009

OPKO Health, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other
Jurisdiction of
Incorporation) 001-33528
(Commission
File Number) 75-2402409
(IRS Employer
Identification No.)

4400 Biscayne Blvd
Miami, Florida 33137
(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number, including area code: (305) 575-4100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 7.01. Regulation FD Disclosure.

          On November 17, 2009, the Company will present at the Lazard Capital Markets 6th Annual Healthcare Conference. A copy of the Company’s presentation slides is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is available on the OPKO website on the day of the presentation at www.opko.com.

          The information contained in Item 7.01 to this Current Report on Form 8-K and Exhibits 99.1 and 99.2 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing by the Company under the Act.

ITEM 9.01. Financial Statements and Exhibits

(d) Exhibits

Exhibit Number		Description
	99.1	Press Release dated November 16, 2009.
	99.2	Lazard Capital Markets 6th Annual Healthcare Conference Presentation.

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

OPKO Health, Inc.
By	/s/ Adam Logal
	Name:	Adam Logal
	Title:	Executive Director Finance, Chief Accounting Officer and Treasurer

Date November 17, 2009

EX-99.1

Exhibit 99.1

OPKO HEALTH TO PRESENT AT THE LAZARD CAPITAL MARKETS 6^TH ANNUAL HEALTHCARE CONFERENCE

MIAMI, FL— November 16, 2009— OPKO Health, Inc. (NYSE Amex: OPK) today announced that senior management will present at the Lazard Capital Markets 6^th Annual Healthcare Conference on Tuesday, November 17, 2009 at 4:40 PM EST. The conference will be held at the St. Regis Hotel in New York City.

OPKO senior management will provide a review of recent corporate developments.

The Company’s audio presentation and slides will be available by choosing the link on the website at www.opko.com under “Investor Relations”.

About OPKO Health, Inc.

Miami-based OPKO is a specialty healthcare company involved in the discovery, development, and commercialization of proprietary pharmaceutical products, medical devices, vaccines, diagnostic technologies and imaging systems. Initially focused on the treatment and management of ophthalmic diseases, OPKO has since expanded into other areas of major unmet medical need such as oncology, infectious diseases, and neurological disorders.

Contacts:
Steven D. Rubin
305 575-6015

EX-99.2

Exhibit 99.2

Lazard Capital Markets 6th Annual Healthcare Conference November 17 - 18, 2009 New York, NY Jamie Freedman, MD, PhD Executive Vice President, R&D

Cautionary Statement 2 This presentation contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding our ability to build a diverse portfolio of important medical products with significant commercial value, rapidly expand our drug development portfolio, our product development efforts and expected timing thereof, the products' potential benefits, statements regarding rolapitant being a best-in-class product, the timing of clinical trials for our product candidates and the commercial launch of rolapitant, estimates regarding market potential and timing of regulatory approval for our product candidates, our ability to invest in Research and Development, make strategic acquisitions of late stage clinical products and opportunistic acquisitions of mature profit- generating pharmaceutical businesses, and to make investments into high potential biotechnology companies, develop technologies for early detection of diseases such as Alzheimer's and cancer, as well as other non-historical statements. These forward-looking statements are only predictions and reflect our views as of the date they were made, and we undertake no obligation to update such statements. Such statements are subject to many risks and uncertainties that could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments, general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, the possibility of infringing a third party's patents or other intellectual property rights, the uncertainty of obtaining patents covering our products and processes and in successfully enforcing them against third parties, and the possibility of litigation, among other factors.

OPKO Health, Inc. A specialty healthcare company building a diverse portfolio of important medical products with significant commercial value 3

OPKO Summary Expanding portfolio of medical products through internal R&D and licensing/acquisitions Opportunistic acquisitions of mature, profit-generating pharmaceutical businesses Private investments into high potential biotechnology companies 4

Board of Directors Phillip Frost, MD Chairman of the Board & CEO Jane Hsiao, PhD, MBA Vice-Chairman & CTO Steve Rubin, JD Director and Exec. VP Administration Richard Lerner, MD President, The Scripps Research Institute Pascal Goldschmidt, MD Dean, University of Miami School of Medicine Alice Yu, MD, PhD Professor, National Taiwan University and UCSD Robert Baron, Investor Thomas Beier, Former CFO, IVAX Corp. John Paganelli, Investor Richard Pfenniger, Jr., CEO Continucare Corp. 5

Management Team Phillip Frost, MD CEO & Chairman of the Board Jane Hsiao, PhD, MBA Vice-Chairman & Chief Technical Officer Steve Rubin, Exec. VP, Administration Rao Uppaluri, PhD, CFA Sr. VP & Chief Financial Officer Jamie Freedman, MD, PhD Exec. VP R&D 6

Financial History Capital Investment Acuity Pharmaceuticals & Froptix (Pre-acquisition) $20.0 Million eXegenics (Public Company) $16.0 Million The Frost Group (December, 2007) $20.0 Million The Frost Group (September, 2008) $15.0 Million The Frost Group (April 2009) $20.0 Million Outside investors (May 2009) $31.0 Million Series D investment (September 2009) $30.0 Million The Frost Group $8.3 million Outside investors $21.7 million Total Capital Investment $152.0 Million Line of Credit The Frost Group (Fully funded) $12.0 Million Total Funds Invested $164.0 Million 7

OPKO R&D Pipeline 8 Products Mode of Action Indication Pre-Clinical Phase I Phase II Phase III Rolapitant NK1 Receptor Antagonist Emesis Doxovir Anti-Viral Viral Conjunctivitis Civamide Vanilloid Rec Antagonist Dry Eye Aquashunt Drainage Shunt Glaucoma SCH 900978 NK1 Receptor Antagonist Emesis siRNA Gene Silencing AMD Flu Vaccine Hemagglutinin Pan-Influenza (e.g. H1, H3, H5)

Nausea & Vomiting A Steady Growth Market Major markets are N&V associated with chemotherapy and surgery >2 million chemo patients/year in US, EU, & Japan 23 million surgery patients/year in US & EU Mainstay of prevention are 5-HT3 antagonists and NK-1 antagonist (Emend(r)) 5-HT3 and NK-1 complementary with additive activity when combined Emesis market estimated at $2B+ Most 5-HT3 antagonists generic by 2010 9

Rolapitant Potential Best-in-Class NK-1 Rolapitant acquired from Schering-Plough (Nov 2009) related to merger with Merck Phase 2 completed for chemotherapy and post-operative N&V (CINV/PONV) Oral and IV formulation in development Patent exclusivity for next 15+ years 10

Phase 2 Positive for PONV Significant reduction in emesis acute (24 hr) and delayed (120 hrs) 0.9 1 N=619 * * * * 58% 70% 73% 80% 87% 78% 52% 57% 76% 73% 62% 0.5 0.6 0.7 0.8 onse (%) * N 47% 0.1 0.2 0.3 0.4 Respo 0 PLA R 5 R 20 R 70 R 200 OND No Emesis 0-24 No Emesis 0-120 11 *Statistically significant when compared to placebo. OPKO La

Rolapitant Differentiation and Plans Key properties that make rolapitant profile better than competition ("best-in-class") No clinically significant drug-drug interactions Single dose regimen offering durable protection (5 days post dose) First to document sustained benefit of 5 day protection in PONV 1st indication PONV with potential launch in next 2-3 years 12

Influenza 200,000 hospitalizations and 46,000 deaths in U.S. each year Economic costs in U.S. ~$80 billion a year Annual "flu shot" against common strains Flu vaccine grown in chicken eggs Limitations: New vaccine each year Only partially protective Manufacturing capacity limited 13

Universal Flu Vaccine Preclinical Development Universal flu vaccine licensed from Academia Sinica July 2009 Vaccine based on modified hemagglutinin Broad protection against variants High potency Preclinical development initiated Large-scale manufacturing process being determined 14

HA-Specific Antibody Response A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses Ming-Wei Chen*+, Ting-Jen Rachel Cheng*, Yaoxing Huang+, Jia-Tsrong Jan*, Shiou-Hwa Ma*, ALice L. Yu*, Chi-Huey Wong*, and David D. Ho* 10000 1000 100 50 0 5 10 15 20 25 30 Amount of pCHA5(ug) 15 [PNAS 2008]

Molecular Diagnostics Overview Global molecular diagnostic market projected to reach ~$4B by 2010 Largest growth segments Early detection Companion diagnostics 16

Molecular Diagnostics Small Molecule Microarray Molecular microarray technology acquired June 2009 "Peptoids" as first example of small molecule array to detect disease- associated antibodies Broad application for diagnosing diseases by a simple blood test Neurological disorders (Alzheimers Disease) Cancers (e.g. Lung, Pancreatic) Other Diseases 17

Small Molecule Microarray Peptoid Methodology 18 HEALTHY DISEASE

Small Molecule Microarray Diagnosis of Alzheimers Disease AD most common form of dementia Diagnosis relies on cognition tests and expensive imaging Molecular test would be useful in drug development 19 NC=Normal Control AD=Alzheimers Disease PD=Parkinson's Disease

Multiple Peptoid Applications 20 Application Example Diagnostic Detection of disease and subpopulations Tissue-specific imaging agents Biomarkers to follow disease and response to therapy Therapeutic Identification of therapeutic targets Modulation of therapeutic targets (agonist or antagonist) Vaccine Antibody based vaccines T-cell based vaccines Dendritic cell therapy

Wide range of ultrasound products A-Scan, B-Scan, 3D-Scan, UBM Distributed in 45 countries Ultrasound market ~$60M a year OPKO Instruments Ultrasound 21

OCT and SLO from single source Precise pixel-to-pixel correlation of coronal OCT slice to SLO surface image Ultra-high resolution imaging of eye Diagnosis of retinal and other eye diseases 22 OPKO Instruments Integrated OCT and SLO OCT SLO OCT=Ocular coherence tomography SLO=Scanning laser ophthalmoscopy

OPKO Instruments Microperimetry Add-On to OCT-SLO Tests retinal function at level of photoreceptors in macula Functional-anatomical correlation Track visual function response to treatment Functional Sensitivity Map ~$250M annual market potential

Pharma Genexx Overview OPKO acquired Pharma Genexx (Chile) in Oct 2009 Rapidly growing sales and profits in Latin America Commercializing >90 products in multiple therapeutic areas 24

Pharma Genexx Total Sales US$ in millions 0 2 4 6 8 10 12 14 16 18 2007 2008 2009 Forecast US$ in millions 25

Minority Interest Platform for human monoclonal antibodies 26 Protein structure-based anti-viral therapeutics Broad spectrum CoCrystal Discovery Inc.

OPKO Summary Rapid expansion of drug development portfolio, including late stage compounds Profitable pharmaceutical companies acquired Minority interest in high potential biotechnology companies 27